Overview
Clarity Pharmaceuticals has announced that the U.S. Food and Drug Administration (FDA) has granted fast track designation for its 64Cu-SAR-bisPSMA, a diagnostic agent designed for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA) positive prostate cancer lesions in patients suspected of having metastasis and who are candidates for initial definitive therapy.
About 64Cu-SAR-bisPSMA
- 64Cu-SAR-bisPSMA represents a significant advancement in prostate cancer diagnosis.
- This innovative product enables next-day imaging and has demonstrated higher tumor uptake and retention, along with the ability to detect much smaller lesions.
Impact of Longer half Life
- The longer half-life of copper-64 also results in an extended shelf-life compared to currently available diagnostic radiopharmaceuticals, facilitating centralized manufacturing and broader distribution while supporting more flexible patient scheduling—advantages not offered by gallium-68 and fluorine-18 based diagnostics.
Clinical Program Groups: -
The ongoing clinical program for 64Cu-SAR-bisPSMA includes trials in two key patient groups:
those with prostate cancer scheduled for radical prostatectomy, and those experiencing biochemical recurrence (BCR) of the disease.
Phase I PROPELLER Study Results
The completed Phase I PROPELLER study yielded favorable safety and efficacy results in patients prior to radical prostatectomy, leading to the initiation of a registrational Phase III trial, CLARIFY, which is currently recruiting participants.
About Phase I/II COBRA Trial
- Concurrently, the Phase I/II COBRA trial demonstrated that 64Cu-SAR-bisPSMA is both safe and highly effective in detecting prostate cancer lesions in patients with BCR. Based on the promising outcomes of the COBRA study, Clarity is planning a second registrational Phase III imaging trial.
- The FDA’s fast track designation is supported by initial clinical evidence suggesting that 64Cu-SAR-bisPSMA may offer superior lesion detection compared to existing prostate cancer diagnostics.
This designation underscores the potential of 64Cu-SAR-bisPSMA to provide a novel diagnostic solution for prostate cancer patients, addressing the limitations of current-generation diagnostic radiopharmaceuticals.
